Golidocitinib Combined With Mitoxantrone Hydrochloride Liposome or Chidamide in the Treatment of Relapsed or Refractory Peripheral T-cell Lymphoma

Abroad (travel likely)RecruitingPHASE1, PHASE2

Conditions

Peripheral T Cell Lymphoma

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Sun Yat-sen Universitiy Cancer Center, Sun Yat-Sen University, Guangzhou, Guangdong, China

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

A Randomized, Double-blind, Multicenter Phase III Study of XNW5004 Tablets in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma

Relapsed/Refractory Peripheral T Cell Lymphoma

Abroad (travel likely)RecruitingPHASE3

Beijing, China

Study of Mogamulizumab With DA-EPOCH or CHOEP in Patients With Aggressive T-cell Lymphoma

T Cell Lymphoma · T-cell Lymphoma

Abroad (travel likely)RecruitingPHASE2

New Haven, United States · New York, United States

CD30 CAR for Relapsed/Refractory CD30+ T Cell Lymphoma

Peripheral T Cell Lymphoma

Abroad (travel likely)RecruitingPHASE2

Chapel Hill, United States · Winston-Salem, United States

GVM±R in Patients With Relapsed or Refractory Aggressive NHL.

Peripheral T Cell Lymphoma · Diffuse Large B-cell Lymphoma

Abroad (travel likely)RecruitingPHASE2

Tianjin, China